Assess whether pediatric studies are necessary or waivable from pediatric

Situation

In an RWE group proposing a post-marketing study instead of a new RCT, pediatric investigation plan vs. disease epidemiology is the evidence after a site-change that invalidates stability claims. Clinical-development physician has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways close using pediatric investigation plan vs. disease epidemiology.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims.

Hypotheses to test

• The population in pediatric investigation plan vs. disease epidemiology is the one a site-change that invalidates stability claims named, so Pediatric studies are necessary follows for this CMC and Development Pathways file.
• The population in pediatric investigation plan vs. disease epidemiology is adjacent only to a site-change that invalidates stability claims; Waivable is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained a site-change that invalidates stability claims before pediatric investigation plan vs. disease epidemiology arrived; no new CMC and Development Pathways path.
• Provenance on pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether pediatric investigation plan vs. disease epidemiology supports the labeled claim clinical-development physician would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read pediatric investigation plan vs. disease epidemiology against a site-change that invalidates stability claims and write the one fact that would move pediatric studies are necessary for clinical-development physician.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (pediatric investigation plan vs. disease epidemiology after a site-change that invalidates stability claims). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.